Cargando…

Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality

BACKGROUND: The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) to chronic myeloid leukemia (CML) therapy has revolutionized the treatment of this disease. Although regular TKI intake is a prerequisite for successful therapy, it has been shown that a significant proportion of patients are...

Descripción completa

Detalles Bibliográficos
Autores principales: Rychter, Anna, Miniszewska, Joanna, Góra-Tybor, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854114/
https://www.ncbi.nlm.nih.gov/pubmed/36658586
http://dx.doi.org/10.1186/s13030-023-00261-w
_version_ 1784873046551560192
author Rychter, Anna
Miniszewska, Joanna
Góra-Tybor, Joanna
author_facet Rychter, Anna
Miniszewska, Joanna
Góra-Tybor, Joanna
author_sort Rychter, Anna
collection PubMed
description BACKGROUND: The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) to chronic myeloid leukemia (CML) therapy has revolutionized the treatment of this disease. Although regular TKI intake is a prerequisite for successful therapy, it has been shown that a significant proportion of patients are non-compliant. Recently there is growing evidence that personality traits may influenced the tendency for non-adherence to treatment in patients with chronic diseases. As far as we know, such a relationship in patients with CML has not been examined, yet. The aim of our study was to determine if personality traits favor non-adherence to treatment recommendations. We investigated the relationship between five-factor model personality factors (conscientiousness, neuroticism, agreeableness, extraversion, and openness) and medication non-adherence. We also checked if the patients with type A and type D personality, were at higher risk of poor medication adherence. METHODS: The following tools were used: self-constructed survey, the NEO-Five Factor Inventory, the Framingham Type A Scale, the D-Scale 14. The study included 140 CML patients treated with imatinib, dasatinib, or nilotinib. RESULTS: 39% of patients reported skipping at least one dose of medication in the month prior to follow-up visit. 51% admitted to skipping such doses from the start of their treatment to the time at which our assessment was performed. We did not find any relationship between the mean values of the analyzed factors of the Big Five (neuroticism, extraversion, openness, agreeableness, conscientiousness) and adherence. However, our analysis revealed that CML patients who admitted to missing doses of drugs during the entire course of treatment demonstrated greater intensity of type A personality traits (p = 0.020). Regarding both factors of type D personality, it was revealed that higher level of negative affectivity significantly decreased the adherence (p = 0.020). CONCLUSION: The results of our study indicate that screening for type D and A personalities may help to identify patients who are at higher risk of poor medication adherence.
format Online
Article
Text
id pubmed-9854114
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98541142023-01-21 Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality Rychter, Anna Miniszewska, Joanna Góra-Tybor, Joanna Biopsychosoc Med Short Report BACKGROUND: The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) to chronic myeloid leukemia (CML) therapy has revolutionized the treatment of this disease. Although regular TKI intake is a prerequisite for successful therapy, it has been shown that a significant proportion of patients are non-compliant. Recently there is growing evidence that personality traits may influenced the tendency for non-adherence to treatment in patients with chronic diseases. As far as we know, such a relationship in patients with CML has not been examined, yet. The aim of our study was to determine if personality traits favor non-adherence to treatment recommendations. We investigated the relationship between five-factor model personality factors (conscientiousness, neuroticism, agreeableness, extraversion, and openness) and medication non-adherence. We also checked if the patients with type A and type D personality, were at higher risk of poor medication adherence. METHODS: The following tools were used: self-constructed survey, the NEO-Five Factor Inventory, the Framingham Type A Scale, the D-Scale 14. The study included 140 CML patients treated with imatinib, dasatinib, or nilotinib. RESULTS: 39% of patients reported skipping at least one dose of medication in the month prior to follow-up visit. 51% admitted to skipping such doses from the start of their treatment to the time at which our assessment was performed. We did not find any relationship between the mean values of the analyzed factors of the Big Five (neuroticism, extraversion, openness, agreeableness, conscientiousness) and adherence. However, our analysis revealed that CML patients who admitted to missing doses of drugs during the entire course of treatment demonstrated greater intensity of type A personality traits (p = 0.020). Regarding both factors of type D personality, it was revealed that higher level of negative affectivity significantly decreased the adherence (p = 0.020). CONCLUSION: The results of our study indicate that screening for type D and A personalities may help to identify patients who are at higher risk of poor medication adherence. BioMed Central 2023-01-19 /pmc/articles/PMC9854114/ /pubmed/36658586 http://dx.doi.org/10.1186/s13030-023-00261-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Short Report
Rychter, Anna
Miniszewska, Joanna
Góra-Tybor, Joanna
Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality
title Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality
title_full Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality
title_fullStr Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality
title_full_unstemmed Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality
title_short Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality
title_sort personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type a and d personality
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854114/
https://www.ncbi.nlm.nih.gov/pubmed/36658586
http://dx.doi.org/10.1186/s13030-023-00261-w
work_keys_str_mv AT rychteranna personalitytraitsfavourablefornonadherencetotreatmentinpatientswithchronicmyeloidleukaemiaroleoftypeaanddpersonality
AT miniszewskajoanna personalitytraitsfavourablefornonadherencetotreatmentinpatientswithchronicmyeloidleukaemiaroleoftypeaanddpersonality
AT goratyborjoanna personalitytraitsfavourablefornonadherencetotreatmentinpatientswithchronicmyeloidleukaemiaroleoftypeaanddpersonality